These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29946319)

  • 1. Resolvin E1 Promotes Bone Preservation Under Inflammatory Conditions.
    El Kholy K; Freire M; Chen T; Van Dyke TE
    Front Immunol; 2018; 9():1300. PubMed ID: 29946319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolvin E1 and chemokine-like receptor 1 mediate bone preservation.
    Gao L; Faibish D; Fredman G; Herrera BS; Chiang N; Serhan CN; Van Dyke TE; Gyurko R
    J Immunol; 2013 Jan; 190(2):689-94. PubMed ID: 23241890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast Differentiation.
    Funaki Y; Hasegawa Y; Okazaki R; Yamasaki A; Sueda Y; Yamamoto A; Yanai M; Fukushima T; Harada T; Makino H; Shimizu E
    Yonago Acta Med; 2018 Mar; 61(1):8-18. PubMed ID: 29599617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of resolvin D1 and resolvin E1 on cementoblast function.
    Bozkurt SB; Hakki SS; Kantarci A
    J Periodontol; 2023 Nov; 94(11):1351-1362. PubMed ID: 37322861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminothiazoles inhibit osteoclastogenesis and PGE
    Kats A; Gerasimcik N; Näreoja T; Nederberg J; Grenlöv S; Lagnöhed E; Desai S; Andersson G; Yucel-Lindberg T
    J Cell Mol Med; 2019 Feb; 23(2):1152-1163. PubMed ID: 30506812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.
    Sato T; Watanabe K; Masuhara M; Hada N; Hakeda Y
    J Bone Miner Metab; 2007; 25(1):19-27. PubMed ID: 17187190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
    Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
    Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease.
    Stalvey MS; Clines KL; Havasi V; McKibbin CR; Dunn LK; Chung WJ; Clines GA
    PLoS One; 2013; 8(11):e80098. PubMed ID: 24236172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolvin E1 regulates osteoclast fusion via DC-STAMP and NFATc1.
    Zhu M; Van Dyke TE; Gyurko R
    FASEB J; 2013 Aug; 27(8):3344-53. PubMed ID: 23629863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK-3β inhibition suppresses instability-induced osteolysis by a dual action on osteoblast and osteoclast differentiation.
    Amirhosseini M; Madsen RV; Escott KJ; Bostrom MP; Ross FP; Fahlgren A
    J Cell Physiol; 2018 Mar; 233(3):2398-2408. PubMed ID: 28731198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption.
    Herrera BS; Ohira T; Gao L; Omori K; Yang R; Zhu M; Muscara MN; Serhan CN; Van Dyke TE; Gyurko R
    Br J Pharmacol; 2008 Dec; 155(8):1214-23. PubMed ID: 18806821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.